Table 1. Characteristics of groups of patients included in the study.

Characteristics (median [IQR])	PHI1 patients from ANRS OPTIPRIM trial	HIC2 from ANRS CO18 cohort
Number of patients	50	46
Days since infection	35 [31–43]	>1825
Fiebig Stage	IV [III–V]	NA3
HLA
% of B*27 patients	2	9
% of B*57 patients	2	35
Age	38 [28–47]	46 [40–52]
Log HIV RNA VL (copies/ml)	5.42 [4.99–5.88]	<1.6[<1.3–1.7]
CD4 T cells (cells/µl)	466 [362–652]	841 [759–1114]
CD8 T cells (cells/µl)	1124 [715–1654]	840 [640–1018]

¹PHI, Primary HIV Infection;

²HIC: HIV controllers;

³NA: not applicable.